Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback